These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

701 related articles for article (PubMed ID: 36801630)

  • 1. Identifying non-nucleoside inhibitors of RNA-dependent RNA-polymerase of SARS-CoV-2 through per-residue energy decomposition-based pharmacophore modeling, molecular docking, and molecular dynamics simulation.
    Aziz S; Waqas M; Mohanta TK; Halim SA; Iqbal A; Ali A; Khalid A; Abdalla AN; Khan A; Al-Harrasi A
    J Infect Public Health; 2023 Apr; 16(4):501-519. PubMed ID: 36801630
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Identification of SARS-CoV-2 RNA dependent RNA polymerase inhibitors using pharmacophore modelling, molecular docking and molecular dynamics simulation approaches.
    Pundir H; Joshi T; Pant M; Bhat S; Pandey J; Chandra S; Tamta S
    J Biomol Struct Dyn; 2022; 40(24):13366-13377. PubMed ID: 34637693
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacophore screening to identify natural origin compounds to target RNA-dependent RNA polymerase (RdRp) of SARS-CoV2.
    Mishra A; Rathore AS
    Mol Divers; 2022 Oct; 26(5):2613-2629. PubMed ID: 35000060
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Identification of RdRp inhibitors against SARS-CoV-2 through E-pharmacophore-based virtual screening, molecular docking and MD simulations approaches.
    Rehman HM; Sajjad M; Ali MA; Gul R; Naveed M; Aslam MS; Shinwari K; Bhinder MA; Ghani MU; Saleem M; Rather MA; Ahmad I; Amin A
    Int J Biol Macromol; 2023 May; 237():124169. PubMed ID: 36990409
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Screening of Severe Acute Respiratory Syndrome Coronavirus 2 RNA-Dependent RNA Polymerase Inhibitors Using Computational Approach.
    Dhankhar P; Dalal V; Kumar V
    J Comput Biol; 2021 Dec; 28(12):1228-1247. PubMed ID: 34847746
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of FDA approved drugs against SARS-CoV-2 RNA dependent RNA polymerase (RdRp) and 3-chymotrypsin-like protease (3CLpro), drug repurposing approach.
    Molavi Z; Razi S; Mirmotalebisohi SA; Adibi A; Sameni M; Karami F; Niazi V; Niknam Z; Aliashrafi M; Taheri M; Ghafouri-Fard S; Jeibouei S; Mahdian S; Zali H; Ranjbar MM; Yazdani M
    Biomed Pharmacother; 2021 Jun; 138():111544. PubMed ID: 34311539
    [TBL] [Abstract][Full Text] [Related]  

  • 7. 25 (S)-Hydroxycholesterol acts as a possible dual enzymatic inhibitor of SARS-CoV-2 M
    Alzahrani FA; Alkarim SA; Hawsawi YM; Abdulaal WH; Albiheyri R; Kurdi B; Alguridi H; El-Magd MA
    J Biomol Struct Dyn; 2023 Jul; 41(10):4744-4755. PubMed ID: 35510619
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Potential Novel Thioether-Amide or Guanidine-Linker Class of SARS-CoV-2 Virus RNA-Dependent RNA Polymerase Inhibitors Identified by High-Throughput Virtual Screening Coupled to Free-Energy Calculations.
    Jukič M; Janežič D; Bren U
    Int J Mol Sci; 2021 Oct; 22(20):. PubMed ID: 34681802
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Dynamics and binding affinity of nucleoside and non-nucleoside inhibitors with RdRp of SARS-CoV-2: a molecular screening, docking, and molecular dynamics simulation study.
    Chinnamadhu A; Ramakrishnan J; Suresh S; Ramadurai P; Poomani K
    J Biomol Struct Dyn; 2023 Dec; 41(20):10396-10410. PubMed ID: 36510678
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular dynamics simulation, 3D-pharmacophore and scaffold hopping analysis in the design of multi-target drugs to inhibit potential targets of COVID-19.
    Fayyazi N; Mostashari-Rad T; Ghasemi JB; Ardakani MM; Kobarfard F
    J Biomol Struct Dyn; 2022; 40(22):11787-11808. PubMed ID: 34405765
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Black tea bioactives as inhibitors of multiple targets of SARS-CoV-2 (3CLpro, PLpro and RdRp): a virtual screening and molecular dynamic simulation study.
    Gogoi M; Borkotoky M; Borchetia S; Chowdhury P; Mahanta S; Barooah AK
    J Biomol Struct Dyn; 2022 Sep; 40(15):7143-7166. PubMed ID: 33715595
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Targeting the SARS-CoV-2 RNA-dependent RNA polymerase (RdRp) with synthetic/designer unnatural nucleoside analogs: an in silico study.
    Bag SS; Sinha S; Dutta S; Baishya HJ; Paul S
    J Mol Model; 2023 Nov; 29(12):366. PubMed ID: 37950101
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Virtual screening of phytochemicals by targeting multiple proteins of severe acute respiratory syndrome coronavirus 2: Molecular docking and molecular dynamics simulation studies.
    Azeem M; Mustafa G; Mahrosh HS
    Int J Immunopathol Pharmacol; 2022; 36():3946320221142793. PubMed ID: 36442514
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Prediction of potential inhibitors for RNA-dependent RNA polymerase of SARS-CoV-2 using comprehensive drug repurposing and molecular docking approach.
    Parvez MSA; Karim MA; Hasan M; Jaman J; Karim Z; Tahsin T; Hasan MN; Hosen MJ
    Int J Biol Macromol; 2020 Nov; 163():1787-1797. PubMed ID: 32950529
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Design, synthesis, docking, and biochemical characterization of non-nucleoside SARS-CoV-2 RdRp inhibitors.
    Brindani N; Munafò F; Menichetti A; Donati E; Nigro M; Ottonello G; Armirotti A; De Vivo M
    Bioorg Med Chem; 2023 Feb; 80():117179. PubMed ID: 36716583
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Identification of a novel dual-target scaffold for 3CLpro and RdRp proteins of SARS-CoV-2 using 3D-similarity search, molecular docking, molecular dynamics and ADMET evaluation.
    Aouidate A; Ghaleb A; Chtita S; Aarjane M; Ousaa A; Maghat H; Sbai A; Choukrad M; Bouachrine M; Lakhlifi T
    J Biomol Struct Dyn; 2021 Aug; 39(12):4522-4535. PubMed ID: 32552534
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Strategic analyses to identify key structural features of antiviral/antimalarial compounds for their binding interactions with 3CLpro, PLpro and RdRp of SARS-CoV-2:
    Dhote AM; Patil VR; Lokwani DK; Amnerkar ND; Ugale VG; Charbe NB; Bhongade BA; Khadse SC
    J Biomol Struct Dyn; 2022; 40(22):11914-11931. PubMed ID: 34431452
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Revealing the Inhibition Mechanism of RNA-Dependent RNA Polymerase (RdRp) of SARS-CoV-2 by Remdesivir and Nucleotide Analogues: A Molecular Dynamics Simulation Study.
    Wakchaure PD; Ghosh S; Ganguly B
    J Phys Chem B; 2020 Nov; 124(47):10641-10652. PubMed ID: 33190493
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Multidimensional virtual screening approaches combined with drug repurposing to identify potential covalent inhibitors of SARS-CoV-2 3CL protease.
    Wang Y; Gao Q; Yao P; Yao Q; Zhang J
    J Biomol Struct Dyn; 2023; 41(24):15262-15285. PubMed ID: 36961210
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Recent advancements in the discovery of small-molecule non-nucleoside inhibitors targeting SARS-CoV-2 RdRp.
    Zhou B; Chen D; Zhang T; Song C; Zhang X; Lin L; Huang J; Peng X; Liu Y; Wu G; Li J; Chen W
    Biomed Pharmacother; 2024 Feb; 171():116180. PubMed ID: 38266622
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.